SpineThera

Q: Where is SpineThera located?

SpineThera's headquarters are located at 15600 Medina Rd Ste 247, Plymouth, Minnesota, 55447, United States

Q: What is SpineThera's phone number?

SpineThera's phone number is (612) 444-1154

Q: What is SpineThera's official website?

SpineThera's official website is www.spinethera.com

Q: What is SpineThera's Revenue?

SpineThera's revenue is <$5 Million

Q: What industry does SpineThera belong to?

SpineThera is in the industry of: Manufacturing General , Manufacturing

Q: What is SpineThera competition?

SpineThera top competitors include: NeoGen Stem Cell Institute , Acousana , Ausanil , Aquilus Pharmaceuticals Inc

Q: Who is the CEO of SpineThera?

SpineThera's CEO is Jeffrey Missling

Q: How do I contact SpineThera?

SpineThera contact info: Phone number: (612) 444-1154 Website: www.spinethera.com

Q: What does SpineThera do?

SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its proprietary and differentiated sustained-release micro-suspension platform technology. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve o... utcomes, and manage overall treatment costs in markets with few or no approved drugs. The company's lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy. SpineThera, Inc., is based is Medical Alley, Minnesota, the global epicenter of health innovation and care. SpineThera Australia Pty Ltd is a wholly owned subsidiary of SpineThera, Inc., and is the sponsor of the SALIENT study. Read More

Q: What are SpineThera social media links?

SpineThera Linkedin page SpineThera Facebook page SpineThera Twitter page

Manufacturing · Minnesota, United States · <25 Employees

SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its proprietary and differentiated sustained-release micro-suspension platform technology. Our goal is to develop proprietary drugsthat offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. The company's lead investigational drug product, SX600, is a novel formulation of dexamethasone being developed for lumbar radiculopathy. SpineThera, Inc., is based is Medical Alley, Minnesota, the global epicenter of health innovation and care. SpineThera Australia Pty Ltd is a wholly owned subsidiary of SpineThera, Inc., and is the sponsor of the SALIENT study.Read More

Contact

Who is SpineThera

Headquarters

15600 Medina Rd Ste 247, Plymouth, Minnesota, 55447, United States

Phone Number

(612) 444-1154

Website

www.spinethera.com

Revenue

<$5M

Industry

Manufacturing General

Manufacturing

Is this data correct?

View contact profiles from SpineThera

Top Competitors of SpineThera

NeoGen Stem Cell Institute
<25
<$5M
1
Acousana
<25
<$5M
2
Ausanil
<25
<$5M
3
Aquilus Pharmaceuticals Inc
<25
<$5M
4
Spinal Pain Specialists
<25
<$5M
5
Posture Pro
<25
<$5M
6

SpineThera Org Chart

View SpineThera org chart to access information on key employees and get valuable insights about SpineThera organizational structure. The organizational chart highlights the reporting lines within the company, starting with Jeffrey Missling - the Founder & Chief Executive Officer of SpineThera, and followed by additional decision makers: Vicki Gashwiler, Global Vice President, Clinical Operations, and more..

Jeffrey Missling

Founder & Chief Executive Of...

Phone

Vicki Gashwiler

Global Vice President, Clini...

Phone

View Email Formats for SpineThera

SpineThera News & Media

SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Supporting the Potential for Best-In-Class Therapy
PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Supporting the Potential for Best-In-Class Therapy
Dec 7, 2022
www.businesswire.com
Doug Drysdale and Dr. Shaheen Lakhan Join SpineThera Board
PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that biopharma executive Doug Drysdale and physician-scientist Dr. Shaheen Lakhan have joined SpineThera’s board of directors to support the further clinical development of SX600 and expansion of SpineThera’s product development pipeline. “As SpineThera ne
May 16, 2022
www.businesswire.com
SpineThera Awarded $5 Million Grant from Department of Defense
PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of lumbar radiculopathy) announced today that the Department of Defense has awarded the company a grant for $4.97 million that will support development of SX600. The scope of work supported by this grant award includes nonclinical toxicity testing of SX600 and manufacturing process de
Apr 26, 2022
www.businesswire.com
SpineThera to Present at WVSIPP InCube Meeting in Conjunction with ASPN Think Tank
MEDICAL ALLEY, MINNESOTA, UNITED STATES, March 9, 2022 /⁨EINPresswire.com⁩/ -- SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for …
Mar 9, 2022
www.einpresswire.com
SpineThera Announces Addition of Vice President of Global Clinical Operations to Management Team
MEDICAL ALLEY, MINNESOTA, UNITED STATES, September 27, 2021 /⁨EINPresswire.com⁩/ -- SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for …
Sep 27, 2021
www.einpresswire.com